Publications by authors named "V Elalouf"
Article Synopsis
- * Platinum-based chemotherapy is the current standard treatment, but the emergence of immune checkpoint inhibitors has shifted treatment approaches, showing promise especially for metastatic UTUC.
- * Advances in research and technology have enhanced the understanding of UTUC's biological characteristics, and this knowledge could lead to more personalized treatment strategies based on genomic profiles, improving patient outcomes.
Purpose Of Review: The role of a re-transurethral resection (TUR) is clearly demonstrated in T1 high-grade nonmuscle invasive bladder cancer. However, its role remains controversial for Ta high-risk tumors and the recent European guidelines stated that the second look procedure could be avoided for these patients despite harboring a high-risk of both disease recurrence and progression. We aimed to evaluate the added benefit on staging, response to bacillus Calmette-Guérin and oncological outcomes of re-TUR in patients with Ta high-grade nonmuscle invasive bladder cancer.
View Article and Find Full Text PDFIntroduction: Upper urinary tract urothelial carcinoma (UTUC) is a rare disease. Thus, little evidence-based data are available to guide clinical decision-making. The aim of the study was to provide an overview of the currently available prognostic factors for UTUC.
View Article and Find Full Text PDFObjectives: To identify predictive factors of bladder recurrence after radical nephroureterectomy and to evaluate the impact of this event on oncological outcomes.
Methods: We carried out a retrospective analysis of 237 patients treated with radical nephroureterectomy for urothelial carcinoma of the upper tract at our institution from 1998 to 2011. Univariable and multivariable models evaluated the prognostic factors of bladder recurrence, and its impact on recurrence-free survival and cancer-specific survival.